This series of Transl Lung Cancer Res will evaluate current clinical evidence in the still-evolving understanding of the role of ICI in oncogene addicted NSCLC, and the potential pulmonary toxicity associated with ICI.
Editorial on Lung Cancer and The Immune System
Lung cancer and the immune system—current controversies and future opportunities
Review Article on Lung Cancer and The Immune System
Immunotherapy in oncogene addicted non-small cell lung cancer
The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review
A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer
Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer
Exploring natural killer cell immunology as a therapeutic strategy in lung cancer
Emerging and multifaceted role of neutrophils in lung cancer
Holding our breath: the promise of tissue-resident memory T cells in lung cancer
B cells in lung cancer—not just a bystander cell: a literature review
Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors
Brief Report on Lung Cancer and The Immune System
Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation
Disclosure:
The series “Lung Cancer and The Immune System” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Daniel Steinfort served as the unpaid Guest Editor for the series.